Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

COVID-19–related outcomes poor for patients with hematologic disease in ASH registry

Publish date:: December 5, 2020

Key clinical point: Data from a COVID-19 registry suggest patients with hematologic disease may experience substantial morbidity and mortality related to SARS-CoV-2 infection, but do not support discontinuing treatment of the underlying disease for favorable prognosis patients.

Major finding: Overall mortality was 28%. Deaths and poor COVID-19-related outcomes occurred more frequently in poorer-prognosis patients and those with relapsed/refractory disease.

Study details: A report from the ASH Research Collaborative Data Hub including data from 250 patients with hematologic malignancies and COVID-19 infection.

Disclosures: Dr. Wood reported research funding from Pfizer, consultancy with Teladoc/Best Doctors, and honoraria from the ASH Research Collaborative. Coauthors provided disclosures related to Celgene, Madrigal Pharmaceuticals, Pharmacyclics, and Amgen.

Citation:

Wood WA et al. ASH 2020, Abstract 215.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,